Clinical trials: Dermatology
Atopic Dermatitis, Atopic Dermatitis (AD)
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
- Trial name
- INTEGUMENT 3 (NCT07916480)
- Testing
- Roflumilast Cream 0.3%, Vehicle Cream
- Where
- 4 sites in United States
- Volunteers
- 415 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Autologous Fat Graft Harvesting, SVF-gel Preparation and Filling, CO2 Fractional Laser Treatment by Using Acupulse Device
Comparison of SVF-gel Filling and CO2 Fractional Laser on Atrophic Acne Scar Treatment
Background Adipose extracellular matrix/stromal vascular fraction gel（SVF-gel）, which contains adipose-derived stem cells, endothelial cells, smooth muscle cells, pericytes, and other cell components.
- Trial name
- NCT06116162
- Testing
- SVF-gel Filling and CO2 fractional laser
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Xijing Hospital
Skin Lesions
Human-AI Uncertainty Callibration for Improved Skin Lesion Segmentation
The goal of this randomized controlled study is to compare the effect of a new, personalized uncertainty-aware decision model (FDM) to a standard image recognition model in improving the diagnostic accuracy while reducing…
- Trial name
- NCT07468357
- Testing
- Base Model, FDM
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Copenhagen Academy for Medical Education and Simulation
Introduction of Teledermatology Mobile Apps
Teledermatology Mobile App: Patient Facing
This study was designed to measure the impact of two teledermatology apps to provide direct to patient teledermatology follow up care, Patient Viewer and My VA Images, with a trial on access to dermatology care.
- Trial name
- NCT03241589
- Testing
- Direct to patient facing mobile apps introduction
- Where
- 3 sites in United States
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Chronic Hand Eczema
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema…
- Trial name
- NCT06004050
- Testing
- Delgocitinib, Vehicle cream
- Where
- 37 sites in China
- Volunteers
- 362 people
- Sponsor
- LEO Pharma
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Hidradenitis Suppurativa
The Ohio State University Dermatology Biorepository
This study will create and extend a source of clinical specimens for the future study of inflammatory skin disorders.
- Trial name
- NCT03146676
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Dermatology
Comparative Clinical Trial on Neoviderm Skin Emulsion and Connettivi-na 0.2% Cream to Evaluate the Normalization Process of the Skin and Re-duction of Cutaneous Tension and Pain in Patients With Superficial Burns Grade 1 and 2
It is a single centre, randomized (set up or distributed in a deliberately random way), open-label (study participants and researchers both know which treatment the patient is receiving), prospective, interventional…
- Trial name
- NVD01/22 (NCT05805917)
- Testing
- Neoviderm Skin Emulsion medical device, Connettivina 0.2% Cream
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Istituto Ganassini S.p.A. di Ricerche Biochimiche